Despite the use of chemotherapy the treatment of advanced neuroblastoma has remained unsatisfactory and the overall disease-free survival rate for children aged >1 year still does not exceed 10 to 15% 2 years after diagnosis.1-3 Cyclophosphamide and, to a lesser extent, vincristine, gave fairly good responses when used singly.45 When used together, the therapeutic response seemed to be increased6 but did not achieve the results obtained in other solid tumours in childhood.7 8 In two studies on single agents, some patients with stage IV neuroblastoma showed some response to adriamcyin, even patients who had been treated with cyclophosphamide and vincristine previously.9 10 and 15% respectively, for 21-year survival. Two parameters, other than the initial response to chemotherapy, were found to affect the prognosisage at presentation, and gender. Children aged <1 year fared significantly better than older children (Fig. 2) , in the CV (33%) and the CVA (60%) groups. However, the prognosis for patients aged >6 years was no better than for those between 1 and 6 years old, their survival rate being only 9%. As far as gender was concerned, there was a trend in favour of girls (27%) and this was true in the CV-(40%) and CVA-(20%) treated patients. The difference was not statistically significant (P>0 10).
Discussion
In this series of 69 children with advanced neuroblastoma, 46 (69%) patients treated with pulses of CVA responded to chemotherapy but only 23 (57%) treated with pulses of CV responded. However, this higher incidence of responses attributable to adriamycin was not statistically significant (P>0 50). In addition, the use of adriamycin did not prolong the duration of the remission nor did it increase the number of survivors. These data confirm the results published in 1974 by Gasparini et al.11 who, in a small series of 19 patients, found a response rate to CVA of 57%, a median survival time of 17 5 9 % of our patients were alive and free of disease 2i years after diagnosis. However, our data confirm that children aged <1 year fared significantly better, with a survival rate of 50 % (Fig. 2) .13 14 The prognosis for survival was worse in boys; this trend has been noted before. '5 It is concluded that adriamycin did not change the outlook for patients with advanced disease when added to cyclophosphamide and vincristine in this particular 'pulsed' schedule. Before stopping the use of this drug, which is undoubtedly active as a single agent in 30 to 40 % of neuroblastomas,9 other schedules should be tried. It has been claimed, for example, that if adriamycin were to be administered on the day after 6 consecutive days of oral cyclophosphamide, the response rate would be higher than if the drugs were given simultaneously. '6 This clinical effect has been successfully correlated with laboratory studies of the kinetic behaviour of human neuroblastoma17 and clearly should be investigated further. Are there other chemotherapeutic agents which show any promise in the treatment of this lethal neoplasm? Response rates of 20 to 66 % have been reported to cis-Platinum'819 and of 23% to VM-26. 20 We have investigated the effect of highdose melphalan chemotherapy combined with autologous bone marrow grafting and preliminary results2' are encouraging for some patients. We feel that the activity of cis-platinum, VM-26, and melphalan warrants their inclusion in the 'induction' therapy of newly-diagnosed cases of advanced neuroblastoma; analysis of the results of such treatment must examine the contribution of individual agents so that children are not treated unnecessarily with drugs that, while giving respectable response rates as single agents, do not contribute favourably to response, duration, or ultimate survival and which may have significant toxicity.9 
